Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
117%(7 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
1
13%
Ph phase_2
1
13%
Ph phase_4
1
13%
Ph phase_3
5
63%

Phase Distribution

1

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
5(62.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 21 (12.5%)
Phase 35 (62.5%)
Phase 41 (12.5%)

Trials by Status

withdrawn113%
completed675%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
withdrawnphase_1

Diabetes Islet Preservation Immune Treatment

NCT02586831
completedphase_2

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

NCT01373151
completedphase_3

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02171429
completedphase_3

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02163759
completedphase_3

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

NCT02497469
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02586831Phase 1

Diabetes Islet Preservation Immune Treatment

Withdrawn
NCT01373151Phase 2

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Completed
NCT02171429Phase 3

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Completed
NCT02163759Phase 3

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Completed
NCT02497469Phase 3

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Completed
NCT01710358Phase 3

A Study in Moderate to Severe Rheumatoid Arthritis

Completed
NCT00195663Phase 3

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Completed
NCT00796705Phase 4

Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

Terminated

All 8 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
8